# STERIS plc (STE)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-13  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/STE/primer

## Business Model

---
ticker: STE
step: 01
generated: 2026-05-13
source: quick-research
---

### STERIS plc (STE) — Business Overview

#### Business Description
STERIS plc is a global leader in infection prevention, sterilization, and contamination control products and services for healthcare, life sciences, and medical device manufacturing. The company operates across three segments: Healthcare (sterile processing equipment + infection prevention consumables), Applied Sterilization Technologies (AST - contract sterilization services for medical device companies), and Life Sciences (contamination control for biopharmaceutical manufacturing). STERIS divested its Dental segment for $787.5M in early FY2025, sharpening focus on core segments. FY2025 (fiscal year ending March 2025) revenue was $5.5B, up 6% YoY.

#### Revenue Model
Revenue is split across services (~55%), consumables (~25%), and capital equipment (~20%). Services include contract sterilization (AST) and maintenance/repair on installed equipment — highly recurring and sticky. Consumables (sterile processing chemistries, surgical drapes, gowns) are high-frequency repeat purchases. Capital equipment (sterilizers, washers, surgical tables) is more lumpy but builds the installed base. The key dynamic: equipment placement leads to a long tail of recurring services and consumables revenue, creating a razor-and-blade business model.

#### Products & Services
- **Sterilizers & Washers**: Autoclaves, low-temperature sterilizers, endoscope reprocessors for hospital sterile processing departments
- **Infection Prevention Consumables**: Sterile drapes, gowns, instrument protection, reprocessing chemistries
- **AST Contract Sterilization**: Gamma, electron beam, EtO (ethylene oxide), X-ray sterilization for medical device manufacturers; STERIS is the global #1 in this market
- **Life Sciences**: Contamination control chemicals, washers, disinfection systems for biopharma manufacturing environments
- **OR Integration / Surgical Tables**: Surgical table systems, lighting, and equipment management

#### Customer Base & Go-to-Market
Healthcare segment: hospital sterile processing departments, operating rooms, endoscopy suites. AST segment: medical device OEMs (Medtronic, Stryker, BD) outsourcing sterilization of single-use devices. Life Sciences: biopharmaceutical manufacturers (Pfizer, Merck, J&J). High customer retention — once a hospital integrates STERIS systems and protocols, switching costs are high due to staff training, regulatory approvals, and process validation requirements.

#### Competitive Position
STERIS is the global #1 in contract medical device sterilization (AST) and a top-2 player in hospital sterile processing equipment (competing with Getinge and Belimed). The infection prevention/sterilization market has high barriers: regulatory approvals, capital intensity of sterilization facilities, specialized expertise, and long hospital procurement cycles. STERIS has expanded via acquisitions (Synergy Health, ISS, Key Surgical, Cantel Medical) and now has an unmatched global infrastructure with 50+ sterilization facilities across the Americas, Europe, and Asia.

#### Key Facts
- Founded: 1985 (as Innovative Medical Technologies); modern STERIS formed from multiple acquisitions
- Headquarters: Dublin, Ireland (incorporated); operations HQ in Mentor, Ohio
- Employees: ~20,000+
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Equipment
- Fiscal Year: Ends March 31
- Market Cap: ~$20–23B

## Financial Snapshot

---
ticker: STE
step: 04
generated: 2026-05-13
source: quick-research
---

### STERIS plc (STE) — Financial Snapshot

#### Income Statement Summary (Fiscal Year ends March 31)

| Metric | FY2022 | FY2023 | FY2024 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | ~$4.23B | $4.54B | $5.14B | +13.3% |
| Gross Margin | ~45% | ~44% | ~44% | |
| Operating Margin | ~17% | ~16% | ~17% | |
| Net Income | ~$480M | ~$490M | ~$550M | +12% |
| EPS (adjusted) | ~$7.50 | ~$7.90 | ~$9.20 | +16% |

*FY2024 revenue jump (+13.3%) reflects bolt-on acquisitions and organic growth. FY2025 (ending March 2025) revenue: $5.5B (+6% organic); dental divestiture ($787.5M proceeds) removed lower-margin segment. FY2025 adjusted EPS estimated ~$9.25+. Note: services revenue +13% in FY2025; consumables +6%; capital equipment -4%.*

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow (FY2025) | $1.15B |
| Free Cash Flow (FY2025) | $787M (+27% YoY) |
| Free Cash Flow (FY2024) | $620M |
| Dental Segment Divestiture | $787.5M (completed early FY2025) |
| Share Buybacks (FY2025) | $350.6M completed |
| Tariff Headwind (FY2026 est.) | ~$45M pre-tax impact |

#### Key Ratios (approximate)
- P/E: ~28x (adjusted) | EV/EBITDA: ~18–20x | FCF Yield: ~3–4%
- Revenue Growth (FY2025): +6% organic | FCF Growth: +27% YoY
- Services as % of Revenue: ~55% (highest-quality, most recurring)
- Consumables Growth (FY2025): +6-7%

#### Growth Profile
STERIS is a compounding medical device/services platform with predictable mid-to-high single digit organic revenue growth. The business is recession-resistant — hospital sterilization is non-elective and procedure volumes grow with aging demographics. Revenue mix has shifted toward services (sticky, recurring) and away from lumpy capital equipment, improving revenue quality. The Dental divestiture in FY2025 improves EBITDA margin by removing a lower-margin segment. AST (contract sterilization for medical devices) benefits from outsourcing trends as medical device OEMs prefer to use specialized third-party facilities rather than build/maintain their own sterilization infrastructure.

#### Forward Estimates
- FY2026 guidance (ending March 2026): Revenue +6-7% (raised to +8-9% including FX benefits); adjusted EPS $9.90-10.15
- Analyst consensus FY2026 adj. EPS: ~$10.21 (+10.7% YoY)
- Analyst mean price target: $288.43 (~15% upside from ~$251)
- Consensus: 6 Strong Buy, 3 Hold (9 analysts covering)

## Recent Catalysts

---
ticker: STE
step: 12
generated: 2026-05-13
source: quick-research
---

### STERIS plc (STE) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Recession-Resistant Healthcare Infrastructure with Aging Population Tailwind** — Hospital sterile processing and surgical support are non-discretionary functions — operating rooms cannot function without sterilized instruments. This makes STERIS's revenue base far more resilient than most healthcare companies, with minimal exposure to elective procedure volatility. An aging U.S. and global population structurally increases surgical procedure volumes — more hip/knee replacements, cardiovascular procedures, cancer surgeries — all of which require sterilization. STERIS services revenue grew 13% in FY2025 even in a challenging macro environment, demonstrating the secular growth nature of the business.

2. **AST Segment: Medical Device Outsourcing Tailwind + Network Moat** — STERIS's Applied Sterilization Technologies segment is the global leader in contract sterilization for medical device manufacturers. As medical device OEMs (Medtronic, Becton Dickinson, Stryker) pursue capital efficiency, they increasingly outsource sterilization to specialized third-party providers with validated facilities — rather than building/maintaining their own sterilization infrastructure. STERIS operates 50+ sterilization facilities globally, creating a network moat that competitors would need decades and billions to replicate. Each new sterilization facility both adds capacity and locks in long-term customer contracts requiring facility validation.

3. **Dental Divestiture + Share Buybacks + FCF Acceleration = Capital Return Inflection** — The $787.5M Dental segment divestiture proceeds funded the $350.6M buyback in FY2025 while improving margin quality (Dental was lower-margin than core segments). FY2025 FCF of $787M (+27% YoY) demonstrates the operating leverage on the cleaner business mix. Management guidance of 6-7% organic revenue growth with ~$9.90-10.15 adjusted EPS in FY2026 implies continued EPS compounding. As capital equipment orders recover from the FY2025 decline (-4%), operating leverage should accelerate FCF growth. Analyst consensus (6 of 9 analysts at Strong Buy) reflects confidence in the compounding trajectory.

#### Bear Case Risks

1. **Tariff Headwinds Escalating — $45M Impact and Rising** — STERIS manufactures products globally and imports components and finished goods subject to U.S. tariffs. The initial tariff headwind estimate of $30M pre-tax has already been revised upward to $45M, reducing FY2026 EPS by an estimated $0.35-0.40/share. If tariffs escalate further (expanded product categories, retaliatory tariffs on medical device exports), the impact could grow to $70-100M+ — a meaningful drag on a business with $600-700M in adjusted operating income. Medical devices and healthcare equipment are not immune to trade policy disruption, and STERIS's global supply chain creates exposure that purely domestic manufacturers avoid.

2. **Capital Equipment Cyclicality + Hospital Capital Budget Pressure** — Hospitals are facing significant financial pressure from labor costs, reimbursement rate changes, and rising operating costs — constraining their capital budgets for large sterilizer and OR equipment purchases. Capital equipment revenue declined 4% in FY2025, and if hospital CapEx budgets remain under pressure in FY2026, this headwind persists. While services and consumables offset the capital equipment decline, a prolonged hospital CapEx drought would eventually slow the installed base growth that generates the recurring revenue tail — delaying the compounding effect.

3. **Valuation Premium + Margin Expansion Expectations** — STERIS trades at ~28x adjusted P/E and ~18-20x EV/EBITDA — a significant premium to most medtech peers and historical averages. This premium reflects the quality/predictability of the business but leaves limited room for error. Any shortfall in organic growth (if surgical procedure volumes disappoint or hospital spending contracts), margin compression from tariffs/labor costs, or acquisition integration issues would cause significant multiple compression. EtO sterilization regulatory risk (the EPA has been scrutinizing ethylene oxide emissions at AST facilities) is an environmental compliance overhang that could require capital investment or temporary facility shutdowns.

#### Upcoming Events
- **Q1 FY2026 Earnings (May/June 2026)**: FY2026 guidance execution; tariff impact vs. $45M estimate; AST segment recovery
- **Capital Equipment Orders Recovery**: Leading indicator for installed base growth and future services/consumables revenue
- **EPA EtO Regulations**: Any new EPA rules on ethylene oxide emissions at sterilization facilities could require facility modifications or capacity reductions
- **Hospital CapEx Environment**: Quarterly hospital earnings (HCA, Tenet, Universal Health) provide leading indicators for STERIS equipment orders

#### Analyst Sentiment
Bullish: 6 Strong Buy, 3 Hold (of 9 analysts); mean price target $288.43 (+15% upside from ~$251). Consensus rating: "Moderate Buy." Street-high target $300 implies +19% upside. Bulls cite infection prevention market leadership, AST network moat, and compounding FCF. Bears (minority) flag tariff headwinds, premium valuation, and capital equipment weakness. Q1 FY2026 margin expansion and service growth confirmed the bullish narrative continues.

#### Research Date
Generated: 2026-05-13

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/ste
- Full research API: GET /api/v1/research/STE/memo
- Coverage universe: /stocks